ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0075

Proteomic, Transcriptomic, and T-Cell Receptor (TCR) Profiling of Synovial Integrin-Expressing (InEx) T Cells in Axial Spondyloarthritis (axSpA)

Zoya Qaiyum1, Michael Tang2 and Robert Inman2, 1Krembil Research Institute, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada

Meeting: ACR Convergence 2023

Keywords: Genomics and Proteomics, immunology, Inflammation, spondyloarthritis, T-Lymphocyte

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0066–0095) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The strong clinical and genetic associations between axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) underscore the pathogenic role of the gut-joint axis. The prevailing arthritogenic peptide hypothesis suggests that CD8+ T cells mount an immunological response upon recognition of a self or microbial arthritogenic peptide at inflammatory sites such as the gut. This could result in a clonal expansion of these cells, ultimately leading to their aberrant migration to other sites such as the joint. We previously identified a subpopulation of pathogenic mature CD8+ T cells in the axSpA synovial fluid (SF), expressing CD103+ and CD49a+ integrins (InEx cells). The expression of integrins on InEx cells implicates their role in aberrant migration between the gut-joint axis. Whether InEx cells recognize an arthritogenic peptide remains unclear. We hypothesize that InEx cells may incite and perpetuate chronic inflammation in axSpA. To this end, we characterized their T-cell receptor (TCR) repertoire and gene expression profile.

Methods: Patients fulfilling the ASAS classification for axSpA were recruited (n=4). Active joint effusion from these patients is reflective of active joint inflammation which coincided with high disease activity (BASDAI >4). We isolated peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs), followed by FACS-sorting of mature CD8+ T cells and InEx cells. Subsequently, single-cell TCR (both α and β chains) and RNA sequencing were performed on these cell types. An HLA-B27+ reactive arthritis (ReA) sample were used as a comparison since it is the paradigm for antigen-driven inflammation initiated in the gut. Mature CD8+ T cells from ReA PBMCs and SFMCs were also FACS-sorted. These were all compared to HLA-B27+ healthy controls (n=4).

Results: The InEx TCR repertoire from axSpA patients was less diverse than mature CD8+ T cells from axSpA PBMCs or SFMCs, indicating a clonally expanded population. The TCR V/J pairings from the β chain in InEx cells confirm existing literature. Interestingly, their TRBV9/TRBJ2-3 usage was also found in mature CD8+ T cells from ReA SFMCs. Assessing the TCR V region from paired α/β chains revealed that the InEx cells shared similar usage with mature CD8+ T cells from ReA PBMCs or SFMCs: TRBV20-1/TRAV1-2, TRBV6-1/TRAV1-2, and TRBV6-2/TRAV1-2. Further, the CDR3 region of the β chain in InEx cells differed from mature CD8+ T cells from ReA SFMCs by only three amino acids. On a transcript level, InEx cells differed from ReA mature CD8+ T cells based on elevated genes such as CCL4L2, IFITM1, and IFITM2, and downregulated genes such as IL7R, GNLY, and KLRB1.

Conclusion: These observations suggest that the autoimmune mechanism employed by InEx cells could be mediated by HLA-B27+. This may enable them to incite inflammation similarly to ReA due to potential recognition of similar peptides, ultimately driving the selection of specific T cell clones. However, InEx cells’ ability to perpetuate inflammation may be distinct from ReA due to a varied transcriptome. This has important implications for therapeutic designs attempting to target integrin blockade in axSpA.

Supporting image 1

Left panel displaying the Chao1 index, a measure of TCR repertoire diversity, stratified by sample type. Right panel displaying the overlapping alpha and beta TCR chain gene usage of the V region. Highlighted in blue boxes are features similar between InEx and ReA SF and axSpA SF (mature CD8+ T cells) and ReA SF. HC = healthy controls, PB = peripheral blood, SF = synovial fluid.

Supporting image 2

Left panel displaying transcriptome profile of InEx vs mature CD8+ ReA SFMCs on UMAP plots. Genetic profile of InEx cells cluster differently to ReA SF. Right panel displaying differently expressed genes between the two groups, with most informative genes circled in green. UMAP = Uniform Manifold Approximation and Projection. SF = synovial fluid.


Disclosures: Z. Qaiyum: None; M. Tang: None; R. Inman: AbbVie, 2, Eli Lilly, 2, Janssen, 2, Novartis, 2, Sandoz, 2.

To cite this abstract in AMA style:

Qaiyum Z, Tang M, Inman R. Proteomic, Transcriptomic, and T-Cell Receptor (TCR) Profiling of Synovial Integrin-Expressing (InEx) T Cells in Axial Spondyloarthritis (axSpA) [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/proteomic-transcriptomic-and-t-cell-receptor-tcr-profiling-of-synovial-integrin-expressing-inex-t-cells-in-axial-spondyloarthritis-axspa/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/proteomic-transcriptomic-and-t-cell-receptor-tcr-profiling-of-synovial-integrin-expressing-inex-t-cells-in-axial-spondyloarthritis-axspa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology